- Home
- RANI
as 12-17-2024 4:00pm EST
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 73.8M | IPO Year: | 2021 |
| Target Price: | $11.80 | AVG Volume (30 days): | 505.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.44 - $8.75 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Rani Therapeutics Holdings Inc. (RANI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McKinley Kate | RANI | Chief Business Officer | Dec 13 '24 | Buy | $1.67 | 17,960 | $29,993.20 | 17,960 | |
| Imran Talat | RANI | Chief Executive Officer | Dec 9 '24 | Buy | $1.94 | 10,296 | $19,974.24 | 494,751 | |
| South Cone Investments Limited Partnership | RANI | 10% Owner | Oct 15 '24 | Sell | $2.90 | 3,829,360 | $10,141,673.58 | 8,825,932 |
Latest Rani Therapeutics Holdings Inc. News
RANI Breaking Stock News: Dive into RANI Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
a month ago
RANI: Third Quarter Update
GlobeNewswire
a month ago
Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update
GlobeNewswire
a month ago
Rani Therapeutics to Participate in Upcoming Investor Conferences
Simply Wall St.
2 months ago
Allied Gaming & Entertainment And 2 Other US Penny Stocks To Watch
Zacks Small Cap Research
2 months ago
RANI: New Triagonist Data in Weight Loss
GlobeNewswire
2 months ago
Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist
MT Newswires
2 months ago
Top Midday Decliners
MT Newswires
2 months ago
Rani Therapeutics Shares Fall After $10 Million Registered Direct Securities Offering Priced
Compare RANI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RANI Rani Therapeutics Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.